Association between Pro 12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese han population

Clinical Cardiology

Volumn 29, Issue 7, 2006, Pages 300-304

  Li, Lin ^a   Cheng, Long Xian ^a   Nsenga, Ripen ^a   He, Mei An ^b   Wu, Tang Chun ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Myocardial infarction; Peroxisome proliferator activated receptor gamma 2; Polymorphism

Indexed keywords

CELL NUCLEUS RECEPTOR; CHOLESTEROL; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROLINE; TRIACYLGLYCEROL; ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADIPOCYTE; ADULT; AGED; ARTICLE; AUTOANALYZER; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CELL DIFFERENTIATION; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; ENERGY METABOLISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HOMEOSTASIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; ASIAN; ELECTROPHORESIS; GENETICS; MIDDLE AGED;

AGED; ALANINE; ASIAN CONTINENTAL ANCESTRY GROUP; ELECTROPHORESIS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PPAR GAMMA; PROLINE;

EID: 33745905950     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960290706     Document Type: Article

References (18)

1. Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Patel NS, Di Paola R, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C: Rosiglitazone and 15-deoxy-delta12,14-prostaglan-dinJ2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut. Br J Pharmacol 2003;140(2):366-376
2. Calnek DS, Mazzella L, Roser S, Roman J, Hart CM: Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23(1):52-57
3. Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, Fishbein MC, Meehan WP, Hsueh WA: Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000;101(11): 1311-1318
4. Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C, Kadowaki T: The Pro12Ala polymorphism in PPAR-gamma 2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 2000;271(1):212-216
5. Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA: Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-γ2 gene variant. Diabetes Care 2004;27:1365-1368
6. Ridker PM, Cook NR, Cheng S, Erlich HA, Lindpaintner K, Plutzky J, Zee RY: Alanine for proline substitution in the peroxisome proliferator-activated receptor-gamma 2 (PPARG2) gene and the risk of incident myocardial infarction. Arterioscler Thromb Vasc Biol 2003;23(5):859-863
7. Pischon T, Pai JK, Manson JE, Hu FB, Rexrode KM, Hunter D, Rimm EB: Peroxisome proliferator-activated receptor-gamma 2P12A polymorphism and risk of coronary heart disease in US men and women. Arterioscler Thromb Vasc Biol 2005;25(8):1654-1658
8. Schneider J, Kreuzer J, Hamann A, Nawroth PP, Dugi KA: The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-gamma 2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes 2002;51(3):867-870
9. Takata N, Awata T, Inukai K, Watanabe M, Ohkubo T, Kurihara S, Inaba M, Katayama S: Pro12Ala substitution in peroxisome proliferator-activated receptor-gamma 2 is associated with low adiponectin concentrations in young Japanese men. Metabolism 2004;53(12):1548-1551
10. Simon I, Vendrell J, Gutierrez C, Fernandez-Real JM, Vendrell I, Gallart L, Fontova R, Richart C: Pro 12Ala substitution in the peroxisome proliferator-activated receptor-gamma is associated with increased leptin levels in women with type-2 diabetes mellitus. Horm Res 2002;58(3):143-149
11. Zietz B, Barth N, Spiegel D, Schmitz G, Scholmerich J, Schaffler A: Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma 2 (PPAR-gamma 2) is associated with higher levels of total cholesterol and LDL-cholesterol in male Caucasian type 2 diabetes patients. Exp Clin Endocrinol Diabetes 2002;110(2):60-66
12. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Auwerx J, Deeb SS, Amouyel P: Impact of the peroxisome proliferator activated receptor-gamma 2 Pro12Ala polymorphism on adiposity, lipids and non-insulin-dependent diabetes mellitus. Int J Obes Relat Metab Disord 2000;24(2):195-199
13. Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scalissi N, Speranza AC, Hirata MH: Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes Metab 2005;7(5):605-611
14. Memisoglu A, Hu FB, Hankinson SE, Manson JE, De Vivo I, Willett WC, Hunter DJ: Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 2003;12(22):2923-2929
15. Yamauchi T, Kamon J, Waki H, Murakami K, Motojima K, Komeda K, Ide T, Kubota N, Terauchi Y, Tobe K, Miki H, Tsuchida A, Akanuma Y, Nagai R, Kimura S, Kadowaki T: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor-gamma (PPAR-gamma) deficiency and PPAR-gamma agonists improve insulin resistance. J Biol Chem 2001;276(44):41245-41254
16. Yang WS, Jeng CY, Wu TJ, Tanaka S, Funahashi T, Matsuzawa Y, Wang JP, Chen CL, Tai TY, Chuang LM: Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002;25(2):376-380
17. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C: Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 2002;16(9):1027-1040
18. Fonseca VA, Diez J, McNamara DB: Decreasing restenosis following angioplasty: The potential of peroxisome proliferator-activated receptor gamma agonists. Diabetes Care 2004;27(11):2654-2660